Press Room

Press Release / Aug 03, 2007

Hovione’s sales grow 16%

Sales reach USD 93.7 million (EUR 70,2 million) for the fiscal year ended March 31st 2007

Loures, Portugal, July 31st - Hovione announced today that the consolidated sales for the fiscal year ended March 31st 2007 amounted to USD 93.7M, representing a growth of 16% over the previous year.

According to Hovione’s CEO, Guy Villax, “This was a year of strong sales growth despite the continued strengthening of the Euro. The main contribution to this growth came from the business segments in which Hovione has been strategically investing over the last few years. We have recently developed two new business segments: particle design services and formulation development services for inhalation – both technically challenging areas that have limited offer in the market.”

In 2006 Hovione invested approximately USD 12M in R&D, with 140 people working in R&D both in lab and pilot-scale. Hovione supported pharmaceutical research in Europe and in the USA, custom synthesizing the development of more than 40 different pharmaceutical ingredients used in clinical trials all over the world. Over the last 12 months, 7 new patent applications were filed as a result of the research conducted at Hovione.

Geographically, Hovione’s sales in the USA market represented 46% of our total sales (43% in 2005), Europe 30% (29%), Japan 15% (18%) and ROW 5% (5%).

“We face 2007 with optimism. Our goal for this year is very clear – surpass USD 100M. I am confident that we can reach this goal!”, adds Guy Villax.

 

About Hovione
Hovione is a world-class company dedicated to the process development and compliant manufacture of APIs for the Pharmaceutical Industry. With a 48-year track record in process development, quality standard and advanced particle design technologies, Hovione offers APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With FDA inspected plants in Europe and the Far East and a Technology Transfer Centre in New Jersey, no manufacturing partner is better positioned to support API development from gram scale to commercialization.

Also in the Press Room